Bo Wen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6384970/publications.pdf

Version: 2024-02-01

37	1,542	394421 19	330143 37
papers	citations	h-index	g-index

37	37	37	2037
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. Redox Biology, 2022, 52, 102313.	9.0	15
2	Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. European Journal of Medicinal Chemistry, 2021, 211, 113060.	5.5	7
3	Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nature Communications, 2021, 12, 2792.	12.8	17
4	SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression. ACS Medicinal Chemistry Letters, 2021, 12, 996-1004.	2.8	21
5	Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. Cell Reports, 2021, 36, 109420.	6.4	18
6	Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry, 2021, 64, 12831-12854.	6.4	69
7	Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials, 2021, 275, 120910.	11.4	37
8	Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry, 2021, 64, 13487-13509.	6.4	78
9	Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0079221.	3.2	5
10	Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 2021, 74, 103725.	6.1	16
11	Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers. Journal of Oncology Pharmacy Practice, 2020, 26, 794-802.	0.9	12
12	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. AAPS Journal, 2020, 22, 3.	4.4	6
13	Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Science Translational Medicine, 2020, 12, .	12.4	122
14	Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. Journal of Medicinal Chemistry, 2020, 63, 13994-14016.	6.4	11
15	Triterpenoid saponins from the roots of Psammosilene tunicoides. FÃ¬toterapÃ¬Ã¢, 2020, 144, 104596.	2.2	9
16	Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. Journal of Clinical Investigation, 2020, 130, 981-997.	8.2	146
17	Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma. Investigational New Drugs, 2019, 37, 323-330.	2.6	2
18	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€”Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	4.6	12

#	Article	IF	Citations
19	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€"Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467.	4.6	21
20	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 162-174.	4.3	24
21	Complexity of Blocking Bivalent Proteinâ€"Protein Interactions: Development of a Highly Potent Inhibitor of the Meninâ€"Mixed-Lineage Leukemia Interaction. Journal of Medicinal Chemistry, 2018, 61, 4832-4850.	6.4	45
22	Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1744-1749.	2.2	42
23	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. Journal of Medicinal Chemistry, 2017, 60, 3887-3901.	6.4	36
24	Discovery of 4-((3â€²R,4â€²S,5â€²R)-6â€³-Chloro-4â€²-(3-chloro-2-fluorophenyl)-1â€²-ethyl-2â€³-oxodispiro[cyclohexane-1,2â€ Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. Journal of Medicinal Chemistry, 2017, 60, 2819-2839.	6.4	143
25	Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. Molecular Pharmaceutics, 2017, 14, 345-358.	4.6	39
26	In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. Molecular Pharmaceutics, 2017, 14, 4295-4304.	4.6	46
27	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs. Molecular Pharmaceutics, 2017, 14, 4281-4294.	4.6	94
28	Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. AAPS Journal, 2017, 19, 1682-1690.	4.4	22
29	Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. Journal of the American Association for Laboratory Animal Science, 2017, 56, 534-538.	1.2	1
30	Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens. Antimicrobial Agents and Chemotherapy, 2016, 60, 4183-4196.	3.2	10
31	Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Proteinâ€"Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). Journal of Medicinal Chemistry, 2016, 59, 892-913.	6.4	56
32	Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia InÂVivo. Cancer Cell, 2015, 27, 589-602.	16.8	290
33	Diterpenoid lanceolatins Aâ€"G from Cephalotaxus lanceolata and their anti-inflammatory and anti-tumor activities. RSC Advances, 2015, 5, 4126-4134.	3.6	26
34	Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. American Journal of Health-System Pharmacy, 2014, 71, 2061-2065.	1.0	2
35	Chemical constituents from the aerial parts of Psammosilene tunicoides. Phytochemistry Letters, 2014, 9, 59-66.	1.2	6
36	Merrilliadione â€" a Rare Isopropyl (13â†'11)â€abeoâ€9,11â€seco Abietane Diterpene from Illicium merrillianum. European Journal of Organic Chemistry, 2014, 2014, 4753-4758.	2.4	8

#	Article	IF	Citations
37	Simultaneous determination of four volatile compounds in rat plasma after oral administration of Shexiang Baoxin Pill (SBP) by HS-SPDE-GCâ€“MS/MS and its application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 963, 47-53.	2.3	28